Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells

Journal of Immunology

Volumn 162, Issue 11, 1999, Pages 6368-6377

  Blazar, Bruce R ^a,c   Taylor, Patricia A ^a   Panoskaltsis Mortari, Angela ^a   Sharpe, Arlene H ^b   Vallera, Daniel A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; GRAFT VERSUS HOST REACTION; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; BONE MARROW TRANSPLANTATION; GRAFT REJECTION; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HISTOCOMPATIBILITY ANTIGENS; IMMUNOCONJUGATES; LYMPHOCYTE TRANSFUSION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; POSTOPERATIVE PERIOD; SIGNAL TRANSDUCTION; SPLEEN; T-LYMPHOCYTES;

EID: 0033151956     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Jenkins, M. K., and R. H. Schwartz. 1987. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165:302.
2. Schwartz, R. H. 1996. Models of T cell anergy: is there a common molecular mechanism? J. Exp. Med. 184:1.
3. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 114:233.
4. Linsley, P. S., J. L. Greene, P. Tan, J. Bradshaw, J. A. Ledbelter, C. Anasetti, and N. K. Damle. 1992. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J. Exp. Med. 176:1595.
5. Tivol, E. A., F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone, and A. H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541.
6. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, H. Griesser, and T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270: 985.
7. Thompson, C. B., and J. P. Allison. 1997. The emerging role of CTLA-4 as an immune attenuator. Immunity 7:445.
8. Liu, Y. 1997. Is CTLA-4 a negative regulator for T-cell activation? Immunol. Today 18:569.
9. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. H. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405.
10. + T cells in vivo is dependent upon CD28 coslimulation and inhibited by CTLA-4. J. Immunol. 155:1032.
11. Krummel, M. F., and J. P. Allison. 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183:2533.
12. Karandikar, N. J., C. L. Vanerlugt, T. L. Walunas, S. D. Miller, and J. A. Bluestone. 1996. CTLA-4, a negative regulator of autoimmune disease. J. Exp. Med. 184:783.
13. Walunas, T. L., C. Y. Bakker, and J. A. Bluestone. 1996. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183:2541.
14. Perez, V. L., L. Van Parjs, A. Bluckians, X. X. Zheng, T. B. Strom, and A. K. Abbas. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6:411.
15. Wu, Y., Y. Guo, A. Huang, and Y. Liu. 1997. CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion. J. Exp. Med 185:1327.
16. Lin, H., J. C. Rathmell, G. S. Gray, C. B. Thompson, J. M. Leiden, and M.-L. Alegre. 1998. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J. Exp. Med. 188:199.
17. Blazar, B. R., P. A. Taylor, P. S. Linsley, and D. A. Vallera. 1994. In vivo blockade of CD28/CTLA4:B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus host disease across the major histocompatibility complex (MHC) barrier in mice. Blood 83:3815.
18. Blazar, B. R., P. A. Taylor, G. S. Gray, and D. A. Vallera. 1994. The role of T cell subsets in regulating the in vivo efficacy of CTLA4-Ig in preventing graft-versus-host disease in recipients of fully MHC or multiple minor histocompatibility-disparate donor inocula. Transplantation 58:1422.
19. Blazar, B. R., P. A. Taylor, A. Panoskallsis-Mortari, G. S. Gray, and D. A. Vallera. 1995. Co-blockade of the LFA1:1CAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood 85:2607.
20. + cells. J. Immunol. 157:3250.
21. Blazar, B. R., P. A. Taylor, M. B. Boyer, A. Panoskallsis-Mortari, K. B. Gorden, J. P. Allison, and D. A. Vallera. 1997. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-BMT splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. J. Immunol. 159:3460.
22. + cells. J. Exp. Med. 180:307.
23. Vallera, D. A., P. A. Taylor, J. Sprent, and B. R. Blazar. 1994. Role of T cell subsets in bone marrow rejection directed to major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice. Transplantation 57:249.
24. Matzinger, P. 1991. The JAM test: a simple assay for DNA fragmentation and cell death. J. Immunol. Methods 145:185.
25. Panoskaltsis-Mortari, A., P. A. Taylor, T. M. Yaeger, D. Wangensteen, P. B. Bitterman, D. H. Ingbar, D. A. Vallera, and B. R. Blazar. 1997. The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogeneic recipients are due to donor T cell infusion and potentiated by cyclophosphamide. J. Clin. Invest. 100:1015.
26. Mantel, N. 1966. Evaluation of survival data in two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50:163.
27. Wallace, P. M., J. S. Johnson, J. F. MacMaster, K. A. Kennedy, P. Gladstone, and P. S. Linsley. 1994. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 58:602.
28. Hakim, F. T., R. Cepeda, G. S. Gray, C. H. June, and R. Abe. 1995. Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules. J. Immunol. 155:1757.
29. Via, C. S., V. Rus, P. Nguyen, P. Linsley, and W. C. Cause. 1996. Differential effect of CTLA41g on murine graft-versus-host disease (GVHD) development: CTLA41g prevents both acute and chronic GVHD development but reverses only chronic GVHD. J. Immunol. 157:4258.
30. Speiser, D. E., M. F. Bachmann, A. Shahinian, T. W. Mak, and P. S. Ohashi. 1997. Acute graft-versus-host disease without costimulation via CD28. Transplantation 63:1042.
31. Saito, K., J. Sakurai, J. Ohata, T. Kohsaka, H. Hashimoto, K. Okumura, R. Abe, and M. Azuma. 1998. Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28. J. Immunol. 160:4225.
32. Yu, X.-Z., P. J. Martin, and C. Anasetti. 1998. Role of CD28 in acute graft-versus-host disease. Blood 92:2963.
33. Lucas, P. J., I. Negishi, K. Nakayama, L. E. Fields, and D. Y. Loh. 1995. Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. J. Immunol. 154:5757.
34. + T cells. Immunity 7:885.
35. Green, J. M., P. J. Noel, A. I. Sperling, T. L. Walunas, G. S. Gray, J. A. Bluestone, and C. B. Thompson. 1994. Absence of 87-dependent responses in CD28-deficient mice. Immunity 1:501.
36. Fallarino, R., P. E. Fields, and T. F. Gajewski. 1998. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J. Exp. Med. 188:205.
37. Rulifson, I. C., A. I. Sperling, P. E. Fields, F. W. Fitch, and J. A. Bluestone. 1997. CD28 costimulation promotes the production of Th2 cytokines. J. Immunol. 158: 658.
38. Murphy, W. J., L. A. Welniak, D. D. Taub, R. Wiltrout, P. A. Taylor, D. A. Vallera, M. Kopf, D. L. Longo, and B. R. Blazar. 1998. Differential effects on the absence of interferon-γ and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Clin. Invest. 102:1742.
39. + T cell mediated graft-versus-host disease. Transplantation 66:1220.
40. + lymphoid engraftment. J. Immunol. 152:1004.
41. + donor T cells fail to induce experimental acute graft-versus-host disease. J. Immunol. 155:585.
42. + Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. J. Immunol. 157:4811.
43. Leach, D. R., M. F. Krummel, and J. P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734.
44. Yang, Y. F., J. P. Zou, J. Mu, R. Wijesuriya, S. Ono, T. Walunas, J. Bluestone, H. Fujiwara, and T. Hamaoka. 1997. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res. 57:4036.
45. Johnson, B. D., and R. L. Truitt. 1995. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 85:3102.
46. + T cell mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J. Immunol. 158:29.